Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon, and thank you for standing by. At this time, I’d ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.

The Pharma & Biotech market had a relatively muted month. There were a number of companies that experienced strong share ...

TTR stabilizer in clinical development, lived longer and better as shown in the ATTRibute-CM study. This is the only Phase 3 ...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...

Q3 2024 Earnings Call Transcript November 6, 2024Amphastar Pharmaceuticals, Inc. misses on earnings expectations.

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

PRINCETON, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics ... in the first half of calendar 2025. The potential ...

A third of American adults consider sleep one of their top three health priorities, and while most of them prioritize ...

Rodica Ceslov explores the challenges associated with social media in the pharmaceutical industry and the benefits of pushing ... publishing, management consulting, non profit, retail, food ...

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.